NovoCure (NVCR) Amortizatization of Intangibles (2014 - 2026)
NovoCure (NVCR) posted quarterly Amortizatization of Intangibles of -$2.6 million for Q2 2026, up 59.86% year-on-year from -$1.6 million in Q2 2025, and up 0.92% on a QoQ basis from -$2.6 million in Q1 2026.
NovoCure (NVCR) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
NovoCure (NVCR) has reported Amortizatization of Intangibles for 13 consecutive years, with -$2.6 million the latest figure, recorded in Q2 2026.
- Quarterly Amortizatization of Intangibles rose 59.86% year-over-year to -$2.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$15.4 million (up 42.1% YoY) and the FY2025 annual result came in at -$23.3 million, up 9.29% from the prior year.
- Amortizatization of Intangibles climbed to -$2.6 million in Q2 2026 per NVCR's latest filing, from -$2.6 million in the prior quarter.
- Over the last five years, Amortizatization of Intangibles for NVCR reached as high as $827000.0 in Q2 2022 and fell as low as -$7.3 million in Q4 2023.
- A 5-year average of -$4.4 million and a median of -$5.2 million in 2023 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles plunged 2984.05% — and 2026, when it jumped 60.67%.
- Year by year, Amortizatization of Intangibles stood at -$3.3 million in 2022, then tumbled by 121.47% to -$7.3 million in 2023, then rose by 8.12% to -$6.7 million in 2024, then soared by 43.85% to -$3.7 million in 2025, then soared by 30.78% to -$2.6 million in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$2.6 million, -$2.6 million, and -$3.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | NovoCure | 1.97 Bn | 1.53 Bn | 142.48 Mn | -2.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.59 Mn |
| Jun 30, 2026 | -2.59 Mn |
| Mar 31, 2026 | -2.62 Mn |
| Mar 31, 2026 | -2.62 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Mar 31, 2025 | -6.65 Mn |
| Mar 31, 2025 | -6.65 Mn |
| Dec 31, 2024 | -6.67 Mn |
| Dec 31, 2024 | -6.67 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Jun 30, 2024 | -6.85 Mn |
| Jun 30, 2024 | -6.85 Mn |
| Mar 31, 2024 | -5.38 Mn |
| Mar 31, 2024 | -5.38 Mn |